Autobio(SH:603658)2024-08-28 10:29Group 1: Business Performance and Financial Metrics - The company's gross margin improved due to a shift in product structure, with an increase in self-produced products and a decrease in agency products [2] - The gross margin is expected to remain stable or increase as the proportion of self-produced products continues to rise [2] - In the first half of the year, the proportion of chemiluminescence detection projects was 56%, with rapid growth in myocardial, respiratory, and thyroid function detection projects [3] Group 2: Market and Product Development - The company has adjusted prices for relevant products following the implementation of centralized procurement in Jiangxi [1] - The new NGS instruments are expected to obtain medical device registration by the end of this year, with supporting reagent registration taking additional time [1] - The company plans to focus on molecular projects related to respiratory diseases, infectious diseases, personalized medicine, and gastrointestinal series, with over 40 projects expected to be certified in the coming years [3] Group 3: Impact of Policies and Market Trends - The execution of centralized procurement policies may affect gross margins, depending on whether the volume gained from price reductions outweighs the impact of price adjustments [2] - The company’s overseas pricing system differs from domestic pricing, with chemiluminescence products priced lower in the Asia-Pacific region and microbiological products priced similarly to domestic products [2] - The demand for autoimmune testing and allergen detection is expected to grow, indicating potential market expansion [3]